Neuropathic pain develops when the nerves responsible for transmitting pain signals are damaged, inflamed, compressed, or dysfunctional. The source can be peripheral (outside the brain and spinal cord) or central (within the CNS).

1. Peripheral Causes

• Diabetic neuropathy (due to chronic hyperglycemia-induced nerve damage).
• Postherpetic neuralgia (following shingles). Traumatic nerve injury or amputation (phantom limb pain).
• Entrapment neuropathies (e.g., carpal tunnel syndrome, radiculopathy).
• Chemotherapy-induced peripheral neuropathy (CIPN). HIV-associated neuropathy or drug-induced neuropathy.

2. Central Causes

• Spinal cord injury or lesions.
• Stroke or multiple sclerosis leading to central pain syndromes.
• Post-surgical central sensitization after major surgery.

3. Pathophysiological Mechanisms

Neuropathic pain involves multiple, overlapping mechanisms:

• Ectopic discharges: Damaged nerves begin to fire spontaneously. Peripheral sensitization: Increased sensitivity of nociceptors to stimuli.
• Central sensitization: Heightened excitability of spinal cord neurons amplifying pain signals. Loss of inhibitory control: Reduced GABAergic and descending inhibition in the CNS.
• Neuroinflammation: Activation of glial cells (microglia, astrocytes) releases inflammatory mediators (IL-1β, TNF-α, IL-6).
• Ion channel dysfunction: Upregulation of sodium and calcium channels leading to hyperexcitability. This complex interplay makes neuropathic pain persistent, difficult to treat, and resistant to traditional analgesics such as NSAIDs.

Neuropathic pain is often described as burning, shooting, stabbing, or electric shock–like sensations. It can also cause abnormal sensory experiences known as dysesthesias or allodynia. Common symptoms include:

- Spontaneous pain: Burning, tingling, or shooting pain without an obvious stimulus.

- Evoked pain:

• Allodynia: Pain caused by normally non-painful stimuli (e.g., light touch).
• Hyperalgesia: Exaggerated response to mildly painful stimuli.

- Paraesthesia: Tingling, “pins and needles,” or crawling sensations.

- Numbness or reduced sensitivity in affected areas.

- Sleep disturbances and fatigue due to chronic pain.

- Mood disorders: Anxiety, irritability, and depression are common due to long-term discomfort.

Symptoms often follow the distribution of affected nerves (e.g., feet in diabetic neuropathy, dermatomal pattern in postherpetic neuralgia).

1. Clinical Assessment:

• Detailed medical history including onset, location, and nature of pain.
• Physical and neurological examination assessing reflexes, sensation, and muscle strength.
• Screening tools such as: DN4 (Douleur Neuropathique en 4 questions) PainDETECT LANSS (Leeds Assessment of Neuropathic Symptoms and Signs)

2. Laboratory and Electrophysiological Tests

• Nerve conduction studies (NCS) and electromyography (EMG): Detect nerve damage or demyelination.
• Quantitative sensory testing (QST): Measures sensory threshold responses.
• Skin biopsy: Evaluates small fiber neuropathy.
• Blood tests: For diabetes, vitamin B12 deficiency, thyroid dysfunction, or autoimmune markers. Imaging (MRI or CT): Identifies compressive lesions, demyelinating disease, or CNS injury.

Neuropathic pain management requires a multimodal approach—addressing both the underlying cause and pain modulation mechanisms.

1. Non-Pharmacological Approaches

• Patient education and lifestyle modification: Emphasize glucose control in diabetic neuropathy, balanced diet, and physical activity. Physiotherapy and occupational therapy: Maintain mobility and reduce stiffness.
• Psychological support: Cognitive behavioral therapy (CBT) helps patients manage pain-related distress.
• Transcutaneous electrical nerve stimulation (TENS): Provides non-invasive pain relief.
• Acupuncture and mindfulness-based interventions: May offer adjunctive benefits.

2. Pharmacological Treatment

Neuropathic pain typically responds poorly to conventional analgesics (like NSAIDs).Therefore, first-line medications are those that target nerve signal modulation.

a. First-Line Treatments

Antidepressants:

• Tricyclic antidepressants (TCAs): Amitriptyline, nortriptyline — inhibit serotonin and norepinephrine reuptake, enhancing descending inhibition.
• Serotonin-norepinephrine reuptake inhibitors (SNRIs): Duloxetine, venlafaxine — effective for diabetic neuropathy and fibromyalgia.
• Anticonvulsants: Gabapentin and Pregabalin — block α2δ calcium channels to reduce neuronal excitability.

b. Second-Line Treatments

• Topical therapies: Lidocaine 5% patch, capsaicin 8% patch — for localized pain.
• Tramadol or tapentadol: Weak opioids with dual mechanisms (μ-opioid receptor agonist + norepinephrine reuptake inhibition).

c. Third-Line and Adjunctive Options

• Stronger opioids (e.g., oxycodone, morphine) only in refractory cases and under strict supervision.
• NMDA receptor antagonists (e.g., ketamine, memantine) — modulate central sensitization.
• Botulinum toxin injections: For focal neuropathic syndromes.

3. Neuroprotective and “Neurorestorative” Approach

Analogous to the chondroprotective approach in osteoarthritis, a modern paradigm in neuropathic pain focuses on neuroprotection and nerve regeneration rather than just symptom control.

This “neuroprotective” approach aims to:

• Protect neurons from oxidative stress and metabolic injury.
• Enhance mitochondrial health and microvascular perfusion.
• Modulate neuroinflammation and glial activation.
• Support remyelination and axonal repair.

Examples include:

• Alpha-lipoic acid (ALA): Potent antioxidant improving nerve conduction.
• B-vitamins (B1, B6, B12): Support myelin synthesis and neuronal repair.
• Acetyl-L-carnitine: Enhances energy metabolism and nerve regeneration.
• Omega-3 fatty acids: Anti-inflammatory neuroprotective role.
• Novel compounds: NGF (nerve growth factor) modulators, neurotrophic peptides, and small-molecule antioxidants under research.

This holistic approach combines disease modification, nerve protection, and pain modulation, reflecting the next generation of neuropathic pain management in pharmaceuticals.

If untreated, neuropathic pain can lead to:

• Chronic disability and loss of function.
• Severe sleep disturbances.
• Mood disorders (depression, anxiety).
• Social withdrawal and reduced productivity.
• Reduced quality of life and increased healthcare utilization.
• Persistent pain can alter brain connectivity (central reorganization), making treatment progressively harder—highlighting the importance of early and consistent management.

• Control underlying diseases: Maintain optimal blood glucose in diabetics.
• Avoid neurotoxic agents: Monitor chemotherapy and antiretroviral toxicity.
• Nutritional support: Prevent vitamin deficiencies. Early rehabilitation after nerve injury or surgery.
• Education: Inform patients about early warning signs to seek care promptly.

Seek medical advice if you experience:

• Persistent burning, tingling, or electric-shock pain.
• Unexplained numbness or loss of sensation.
• Pain after shingles, trauma, or surgery.
• Weakness or imbalance accompanying sensory changes.
• Chronic pain unresponsive to conventional painkillers.
• Early consultation with a neurologist or pain specialist improves outcomes and prevents irreversible nerve damage

• Treede RD, Jensen TS, et al. Neuropathic pain: redefinition and grading system. Pain. 2008;137:388–392.
• Colloca L, Ludman T, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;3:17002
• Finnerup NB, Kuner R, Jensen TS. Neuropathic pain: from mechanisms to treatment. Physiol Rev. 2021;101(1):259–301.
• Dworkin RH, et al. Pharmacologic management of neuropathic pain. Pain. 2010;149(2):289–305
• Baron R. Mechanisms of neuropathic pain. Nat Clin Pract Neurol. 2006;2:95–108.